Drug stocks take a hit

Gilead shares drop nearly 10% on lowered sales guidance. But the strength of technology shares may be pulling money out of health care.

By Charley Blaine Apr 21, 2010 1:57PM

Updated at 4:55 p.m. ET


Not a good day for health care shares, especially those of Gilead Sciences (GILD).

Gilead makes a number of important drugs used to treat AIDS-related ailments, and its shares were down 9.6% to $40.76. Late Tuesday, it trimmed its guidance for full-year sales.

The loss was the worst among stocks in the Standard & Poor's 500 Index ($INX) and in the Nasdaq-100 Index ($NDX.X).

At the same time, Merck (MRK) was off  3.7% to $34.74 -- the biggest decline among stocks in the Dow Jones Industrial Average ($INDU).

Gilead didn't have a bad quarter. Earnings of 99 cents a share beat Street estimates by 3 cents. Revenue was up 36% to $2.08 billion; the consensus was $2.07 billion. Gilead Sciences

Sales of most of its drugs beat estimates -- except one.

Sales of Atripla, used to treat HIV infection, increased 36% to $692.9 million for the first quarter of 2010, up from $509.9 million in the first quarter of 2009. However, analysts were looking for sales of $726 million.

But another issue is that companies are still taking charges related to the taxation of retirement health benefits under the new heath reform bill. Abbott Laboratories (ABT) included that in explaining why it expects charges totaling 34 cents a share to hit earnings this year. Abbott was down 2.4% to $51.78.

Another is Venezuela's January devaluation of its currency, the bolivar.

But there is also a sense, at least according to Art Hogan, the chief market analyst at Jeffries, that technology shares are sucking money from other parts of the market.

The catalyst: "Strong earnings from the sector, including Apple (AAPL)," he told Reuters.


Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.



Quotes delayed at least 15 min
Sponsored by:


There’s a problem getting this information right now. Please try again later.
There’s a problem getting this information right now. Please try again later.
Market index data delayed by 15 minutes

[BRIEFING.COM] The S&P 500 trades higher by 0.2%.

Just reported, existing home sales hit an annualized rate of 5.15 million units in July, while the Briefing.com consensus expected a reading of 5.00 million. The pace for July was up from the prior month's revised rate of 5.03 million units (from 5.04 million).

The Philadelphia Fed Survey for August jumped to 28.0 from 23.9. Economists polled by Briefing.com had expected that the Survey would slip to 15.5.

The ... More


There’s a problem getting this information right now. Please try again later.
Sponsored by: